Warfarin or novel oral anticoagulants for atrial fibrillation?

The Lancet

Volumn 383, Issue 9921, 2014, Pages 931-933

  Larsen, Torben Bjerregaard ^a,b   Lip, Gregory Y H ^b,c  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN; ANTIVITAMIN K;

ANTICOAGULATION; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL DECISION MAKING; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; META ANALYSIS (TOPIC); NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; ANTICOAGULANT THERAPY; BRAIN ISCHEMIA; DRUG DOSE COMPARISON; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; WARFARIN;

EID: 84896114628     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)62376-4     Document Type: Note

References (11)

1. Lip GY. Recommendations for thromboprophyl axis in the 2012 focused update of the ESC guidelines on atrial fi brillation: a commentary. J Thromb Haemost 2013; 11: 615-26.
2. Camm AJ, Lip GY, De Caterina R, et al. 201 2 focused update of the ESC guidelines for the management of atrial fi brillation: an update of the 2010 ESC guidelines for the management of atrial fi brillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14: 1385-413.
3. Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefi t of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fi brillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012; 107: 584-89.
4. Ruff CT, Giugliano RP, Braunwald E. Compar ison of the effi cacy and safety of new oral anticoagulants with warfarin in patients with atrial fi brillation: a meta-analysis of randomised trials. Lancet 2013; published online Dec 4. http://dx.doi.org/10.1016/ S0140-6736(13)62343-0.
5. Skjoth F, Larsen TB, Rasmussen LH. Indirec t comparison studies-are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fi brillation. Thromb Haemost 2012; 108: 405-06.
6. Kansal AR, Sharma M, Bradley-Kennedy C, et al. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fi brillation in Canada. Comparative effi cacy and cost-eff ectiveness. Thromb Haemost 2012; 108: 672-82.
7. Larsen TB, Rasmussen LH, Skjoth F, et al. Effi cacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fi brillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013; 61: 2264-73.
8. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fi brillation patients. Thromb Haemost 2011; 106: 968-77.
9. Gallego P, Roldan V, Marin F, et al. Cessa tion of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fi brillation. Thromb Haemost 2013; published online Oct 7. http:// dx.doi.org/10.1160/TH13-07-0556.
10. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors aff ecting quality of anticoagulation control among patients with atrial fi brillation on warfarin: the SAMe-TT2R2 score. Chest 2013; 144: 1555-63.
11. Boriani G. Predicting the quality of anti coagulation during warfarin therapy: the basis for an individualized approach. Chest 2013; 144: 1437-38.